Citation: | ZHOU Lei, HUANG Xueshuang, LI Huimin, JIN Xin, WANG Hai. Expression and correlation of four kinds of cytokines in patients with Hashimoto's thyroiditis or papillary thyroid carcinoma[J]. Chinese Journal of General Practice, 2024, 22(7): 1209-1211. doi: 10.16766/j.cnki.issn.1674-4152.003601 |
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
[2] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021[J]. 肿瘤预防与治疗, 2021, 34(12): 1164-1201. https://www.cnki.com.cn/Article/CJFDTOTAL-SCZF202112014.htm
Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology(CSCO)Differentiated Thyroid Cancer[J]. Journal of Cancer Control And Treatment, 2021, 34(12): 1164-1201. https://www.cnki.com.cn/Article/CJFDTOTAL-SCZF202112014.htm
|
[3] |
傅莉萍, 金剑虹, 王保法, 等. 骨化三醇对桥本甲状腺炎患者TPOAb、TgAb、Th17/Treg相关细胞因子的影响[J]. 浙江医学, 2019, 41(22): 2398-2401. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJYE201922015.htm
FU L P, JIN J H, WANG B F, et al. Impact of calcitriol on the thyroid peroxidase antibody, thyroglobulin antibody levels and Th17/Treg related cytokines in serum of patients with Hashimoto's thyroiditis[J]. Zhejiang Medical Journal, 2019, 41(22): 2398-2401. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJYE201922015.htm
|
[4] |
田文. 甲状腺乳头状癌诊治之中国经验与未来走向[J]. 临床外科杂志, 2020, 28(3): 201-204.
TIAN W. The Chinese experience and future trend of thyroid cancer diagnosis and treatment[J]. Journal of Clinical Surgery, 2020, 28(3): 201-204.
|
[5] |
朱旭东. 桥本氏甲状腺炎患者血清TPOAb、TgAb水平与病情的相关性分析[J]. 检验医学, 2018, 33(10): 903-906. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYY201810009.htm
ZHU X D. Serum TPOAb and TgAb levels in Hashimoto's thyroiditis patients and their correlations with disease severity[J]. Laboratory Medicine, 2018, 33(10): 903-906. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYY201810009.htm
|
[6] |
VARRICCHI G, LOFFREDO S, MARONE G, et al. The immune landscape of thyroid cancer in the context of immune checkpoint inhibition[J]. Int J Mol Sci, 2019, 20(16): 3934. DOI: 10.3390/ijms20163934.
|
[7] |
朱冯赟智, 王茜, 何菁, 等. 白介素-2及其受体在自身免疫病发病中作用的研究进展[J]. 中国免疫学杂志, 2023, 39(4): 842-848. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMXZ202304029.htm
ZHU F Y Z, WANG X, HE J, et al. Advances on role of interleukin-2 and its receptors in development of autoimmune diseases[J]. Chinese Journal of Immunology, 2023, 39(04): 842-848. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMXZ202304029.htm
|
[8] |
张滢, 梁楠, 孙辉. 细胞因子与甲状腺乳头状癌: 从分子机制到临床应用的研究现状[J]. 中国实验诊断学, 2022, 26(1): 117-120. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSZD202201035.htm
ZHANG Y, LIANG N, SUN H. Cytokines and papillary thyroid carcinoma: from molecular mechanism to clinical application[J]. Chinese Journal of Laboratory Diagnosis, 2022, 26(1): 117-120. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSZD202201035.htm
|
[9] |
HU J Q, LEI B W, WEN D, et al. IL-2 enhanced MHC class Ⅰ expression in papillary thyroid cancer with Hashimoto's thyroiditis overcomes immune escape in vitro[J]. J Cancer, 2020, 11(14): 4250-4260.
|
[10] |
李娜, 连续. IL-12与Th17在自身免疫性甲状腺疾病中的研究进展[J]. 牡丹江医学院学报, 2020, 41(6): 139-142. https://www.cnki.com.cn/Article/CJFDTOTAL-MDJB202006039.htm
LI N, LIAN X. Research progress of IL-12 and TH17 in autoimmune thyroid disease[J]. Journal of Mudanjiang Medical University, 2020, 41(6): 139-142. https://www.cnki.com.cn/Article/CJFDTOTAL-MDJB202006039.htm
|
[11] |
NGUYEN K G, VRABEL M R, MANTOOTH S M, et al. Localized interleukin-12 for cancer immunotherapy[J]. Front Immunol, 2020, 15(11): 575597. DOI: 10.3389/fimmu.2020.575597.
|
[12] |
曹纪萍, 赵艳峰, 张亚民, 等. EB病毒感染及XRCC1、IL-10基因多态性与甲状腺癌的关联性分析[J]. 现代生物医学进展, 2023, 23(12): 2371-2376. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX202312032.htm
CAO J P, ZHAO Y F, ZHANG Y M, et al. Association of EB Virus Infection and Gene Polymorphisms of XRCC1 and IL-10 with Thyroid Cancer[J]. Progress in Modern Biomedicine, 2023, 23(12): 2371-2376. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX202312032.htm
|
[13] |
代毅, 陈昱幸子, 陈勇, 等. 血清IL-2、IL-6、IL-10与分化型甲状腺癌诊断及侵袭性的相关性分析[J]. 现代实用医学, 2023, 35(5): 620-622, 701. https://www.cnki.com.cn/Article/CJFDTOTAL-NBYX202305018.htm
DAI Y, CHEN Y X Z, CHEN Y, et al. Serum levels of IL-2, IL-6 and Il-10 were correlated with the diagnosis and invasiveness of differentiated thyroid cancer[J]. Modern Practical Medicine, 2023, 35(5): 620-622, 701. https://www.cnki.com.cn/Article/CJFDTOTAL-NBYX202305018.htm
|
[14] |
LU Z W, HU J Q, LIU W L, et al. IL-10 restores MHC Class Ⅰ expression and interferes with immunity in papillary thyroid cancer with hashimoto thyroiditis[J]. Endocrinology, 2020, 161(10): bqaa062. DOI: 10.1210/endocr/bqaa062.
|
[15] |
王惟, 张达容, 黄煜琪, 等. 甲状腺癌患者血清IL-17、IL-35、SIL-2R表达水平及其临床意义[J]. 现代生物医学进展, 2018, 18(4): 729-732. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201804028.htm
WANG W, ZHANG D R, HUANG Y Q, et al. Expressions and Clinical Significance of Serum IL-17, IL-35 and SIL-2R in Patients with Thyroid Cancer[J]. Progress in Modern Biomedicine, 2018, 18(4): 729-732. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201804028.htm
|
[16] |
OZISIK H, CEKIN A, SUNER A, et al. Evaluation of IL-10, MCP-1, IFN gamma, and protectin D1 levels in patients with Hashimoto's thyroiditis[J]. Ir J Med Sci, 2023, 192(1): 177-184.
|
[17] |
ARAQUE K A, GUBBI S, KLUBO-GWIEZDZINSKA J. Updates on the management of thyroid cancer[J]. Horm Metab Res, 2020, 52(8): 562-577.
|
[18] |
朱光亮, 沈俊, 李晓明, 等. 美洛昔康预处理联合超声引导下喉上神经阻滞在甲状腺癌手术患者围术期中的应用[J]. 中华全科医学, 2022, 20(3): 391-394. doi: 10.16766/j.cnki.issn.1674-4152.002360
ZHU G L, SHEN J, LI X M, et al. Application of meloxicam pretreatment combined with ultrasound-guided internal branch of superior laryngeal nerve block in perioperative period of radical thyroidectomy patients[J]. Chinese Journal of General Practice, 2022, 20(3): 391-394. doi: 10.16766/j.cnki.issn.1674-4152.002360
|